Inovio Biomedical Redirects Strategic Emphasis toward DNA Vaccines and DNA Delivery

Company expanding R&D to advance its DNA delivery technology and develop proprietary DNA vaccines for cancer and chronic infectious diseases

11-Oct-2007

Inovio Biomedical Corporation announced it is focusing its research and development efforts on its electroporation-mediated DNA delivery technology and DNA vaccines with the objective of further building potential downstream value to existing and prospective partners. Overall, management has concluded that the potential return on capital invested in Inovio's DNA delivery technology is significantly greater than the potential return on its Selective Electrochemical Tumor Ablation (SECTA) program. Therefore, Inovio will focus its research and development efforts on the DNA vaccine market while pursuing avenues for commercialization of the SECTA therapy. The company's strategy is to:

- Maintain and build Inovio's industry-leading intellectual property and patent estate related to its proprietary electroporation-mediated DNA delivery platform.

- Pursue additional academic and commercial partnerships, adding to license agreements with Merck and Wyeth as well as multiple other partnerships. With five clinical studies in progress, the goal is to build a deep pipeline of preclinical and clinical programs, conducted by partners, that may further validate the potentially pivotal role Inovio's technology may play in delivering and enhancing the potency of promising DNA vaccines as well as identify and validate promising DNA vaccines themselves. Existing partnerships are anticipated to generate future income as pre-defined milestones are achieved and new partnerships would potentially add to future cash flow and further build Inovio's unique and proprietary database regarding electroporation-mediated delivery of DNA-based immunotherapies.

- Support partners in their initiation and execution of DNA vaccine clinical studies.

- Expand Inovio's research and development efforts with the intent to create or acquire and develop promising proprietary DNA vaccines for cancer and chronic infectious disease targets from preclinical stage through to Phase II clinical studies, which can potentially create significant value with relatively nominal capital investment.

https://www.bionity.com/en/news/71536/inovio-biomedical-redirects-strategic-emphasis-toward-dna-vaccines-and-dna-delivery.html